Skip to main content

Table 1 Characteristics of children by intervention group, sulforaphane (SF) or placebo (PL), at baseline

From: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Characteristic SF (n = 22) PL (n = 23) p valuea
Age (years), mean (SD) 7.4 (3.0) 7.0 (2.5) 0.62
Male sex, n (%) 20 (90.9) 20 (90.0) 0.67
Race, n (%) 0.37
 White 17 (77.3) 15 (65.2)  
 Otherb 5 (22.7) 8 (34.8)  
BMI (kg/m2), mean (SD) 16.6 (3.1) 17.4 (3.6) 0.44
Fever responder, n (%) 11 (50.0) 8 (34.8) 0.30
Regression, n (%) 10 (45.5) 6 (26.1) 0.18
Concomitant medications or therapy, n (%) 2 (9.1) 5 (21.7) 0.24
ADOS-2 Calibrated Severity Score, mean (SD) 7.9 (1.4) 7.4 (1.4) 0.31
ADOS-2 social affect score, mean (SD) 13.7 (3.8) 11.8 (3.7) 0.14
ADOS-2 repetitive behaviors score, mean (SD) 4.7 (1.6) 5.7 (1.5) 0.06
Baseline SRS-2 total raw score, mean (SD) 118.2 (26.7) 115.3 (16.6) 0.66
Baseline ABC total score, mean (SD) 74.2 (30.5) 59.7 (23.6) 0.08
Baseline OACIS-S general level of ASD symptoms/behaviors 0.26
 Mild/moderate, n (%) 7 (31.8) 7 (30.4)  
 Marked, n (%) 7 (31.8) 12 (52.2)  
 Severe, n (%) 8 (36.4) 4 (17.4)  
Baseline overall Vineland scorec 57.5 (11.9) 57.6 (6.7) 0.98
Baseline Leiter composite IQ Scorec 70.4 (30.8) 70.8 (22.1) 0.96
  1. BMI body mass index, SRS-2 social responsiveness scale 2, ABC Aberrant Behavior Checklist, OACIS-S Ohio Autism Clinical Impressions Scale (or clinical global impression)—severity, ASD autism spectrum disorders, IQ intelligence quotient
  2. aChi-square for binary or categorical variables; t test for continuous variables
  3. bOther race includes Asian, mixed or unknown
  4. cN = 18 for SF group, N = 22 for PL group